This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Roche's Tecentriq Gets FDA Approval for Difficult Lung Cancer
by Zacks Equity Research
Roche (RHHBY) gets an FDA approval of sBLA for Tecentriq in combination with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).
Large-Cap Pharmaceuticals Industry Outlook: A Recovery Ahead?
by Kinjel Shah
Pipeline success, cost-cutting measures, share buybacks, product launches, ramped up M&A and collaboration activities should keep the sector afloat, going forward.
Novartis' (NVS) Alcon Acquired PowerVision for $285 Million
by Zacks Equity Research
Novartis' (NVS) eye-care unit, Alcon acquires PowerVision to drive growth in advanced technology intraocular lenses (AT-IOLS) for cataract surgery patients.
Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth
by Zacks Equity Research
Inovio's (INO) most advanced candidate, VGX-3100 vaccine, is advancing well. Heavy reliance on partners for funds to develop its pipeline candidates is a persistent concern.
AstraZeneca Up This Year on New Drugs & Pipeline Progress
by Zacks Equity Research
AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.
Top Research Reports for Merck, Adobe & Broadcom
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Merck (MRK), Adobe (ADBE) and Broadcom (AVGO).
AVEO Pharmaceuticals (AVEO) Q4 Earnings Beat, Revenues Lag
by Zacks Equity Research
AVEO Pharmaceuticals' (AVEO) loss is narrower than estimated in Q4. However, revenues fall shy of estimates.
Merck's Keytruda Gets EU Approval for Difficult Lung Cancer
by Zacks Equity Research
Merck (MRK) receives approval for Keytruda's combo therapy for first-line treatment of metastatic squamous non-small cell lung cancer population in Europe.
Here's Why Momentum Investors Will Love Astrazeneca (AZN)
by Zacks Equity Research
Does Astrazeneca (AZN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Britain Headed for a Soft Brexit? 5 Picks
by Swarup Gupta
Following May's fresh legislative defeat, Britain could exit the EU while retaining access to its common market.
Inovio (INO) Misses on Q4 Earnings & Revenues, Shares Down
by Zacks Equity Research
Inovio Pharmaceuticals (INO) reports results for fourth quarter of 2018 wherein loss and revenues both miss estimates.
Bayer Submits Application in EU for Prostate Cancer Drug
by Zacks Equity Research
Bayer (BAYRY) submits an MAA for darolutamide in EU for the treatment of patients with non-metastatic castration-resistant prostate cancer.
Sanofi's Dupixent Gets FDA Priority Status for Nasal Polyps
by Zacks Equity Research
Sanofi (SNY) and partner Regeneron's (REGN) Dupixent gets FDA's priority review status for inadequately controlled severe chronic rhinosinusitis with nasal polyps.
The Zacks Analyst Blog Highlights: J&J, Lilly, Pfizer, AstraZeneca and Merck's
by Zacks Equity Research
The Zacks Analyst Blog Highlights: J&J, Lilly, Pfizer, AstraZeneca and Merck's
Should Value Investors Pick AstraZeneca PLC (AZN) Stock?
by Zacks Equity Research
Is AstraZeneca PLC (AZN) a great pick from the value investor's perspective right now? Read on to know more.
Pharma Stock Roundup: FDA OK's J&J Antidepressant, CHMP Recommends Several Drugs
by Zacks Equity Research
J&J's (JNJ) Spravato (esketamine) gets approval for treatment-resistant depression. CHMP recommends approval of several drugs.
J&J's (JNJ) Nasal Spray Spravato Gets FDA Nod for Depression
by Zacks Equity Research
J&J (JNJ) gets FDA nod for its new nasal spray, Spravato (esketamine) for treatment-resistant depression
Mallinckrodt (MNK) Rallies as Earnings Beat Estimates in Q4
by Zacks Equity Research
Mallinckrodt (MNK) tops earnings and sales estimates in the fourth quarter leading to a gain in share price.
Bayer (BAYRY) Q4 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Bayer's (BAYRY) fourth-quarter 2018 core earnings per share of 31 cents, per American Depositary Receipt ("ADR"), beat the Zacks Consensus Estimate of 26 cents.
Clovis (CLVS) Q4 Earnings Lag Estimates, Rubraca Sales Recover
by Zacks Equity Research
Clovis' (CLVS) top and bottom line miss estimates in the fourth quarter. However, Rubraca sales recover during the quarter.
AstraZeneca/Merck's Lynparza Meets Endpoint in POLO Study
by Zacks Equity Research
AstraZeneca (AZN) and Merck's Lynparza significantly delays disease progression in a late-stage study (POLO) evaluating it as first-line maintenance treatment in pancreatic cancer.
Merck's (MRK) Stock Up Almost 50% in a Year: Here's Why
by Zacks Equity Research
Merck's (MRK) stock is up 45.2% in the past year. Here are reasons for the same.
Strength Seen in AstraZeneca (AZN): Stock Soars 9.3%
by Zacks Equity Research
AstraZeneca (AZN) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Ironwood (IRWD) Q4 Earnings & Revenues Beat, Shares Rise
by Zacks Equity Research
Ironwood (IRWD) beats on both earnings and sales in the fourth quarter. Shares up.
BMY vs. AZN: Which Stock Is the Better Value Option?
by Zacks Equity Research
BMY vs. AZN: Which Stock Is the Better Value Option?